Mecillinam activity against multidrug-resistant Shigella sonnei and Shigella flexneri
Microbiology Spectrum · 04.03.2025 · 13 (3)
DOI: 10.1128/spectrum.01006-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 04.03.2025. Verfasst von Aleksandra Stefanovic und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Microbiology and Virology, St. Paul's Hospital, Providence Health Care, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Shigella flexneri, Shigella sonnei, Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We performed phenotypic susceptibility testing and whole-genome sequencing to investigate in vitro mecillinam activity against multidrug-resistant (MDR) Shigella . Ninety-five isolates (53 [56%] Shigella sonnei and 42 [44%] Shigella flexneri ) were included. The MIC 50 and MIC 90 were 1 and 2 µg/mL, respectively, by agar dilution, and all zone diameters were ≥15 mm by disc diffusion testing. No known clinically relevant mecillinam resistance mutations (including cys B) were detected. The favorable MIC profile and absence of resistance markers make pivmecillinam an agent worth considering for the treatment of infections caused by MDR Shigella . Clinically feasible susceptibility testing methods and standardized interpretations for mecillinam and Shigella spp. are needed to guide therapy. IMPORTANCE Rapidly emerging resistance in Shigella species leaves few antibiotic treatment options. The World Health Organization recommends pivmecillinam, a prodrug of mecillinam, for the treatment of Shigella infections. However, little is known about the susceptibility of Shigella spp. to mecillinam in North America. We performed mecillinam susceptibility testing on our collection of resistant Shigella isolates and investigated genetic mechanisms of resistance using whole-genome sequencing. We observed a favorable mecillinam susceptibility profile and a lack of known genetic mechanisms of resistance. However, in the absence of standardized laboratory guidelines for mecillinam susceptibility testing, interpreting susceptibility test results is challenging. We propose that further studies are needed to correlate susceptibility testing data with clinical outcomes, with the aim of establishing standardized clinical breakpoints for Shigella spp. and mecillinam.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Microbiology and Virology, St. Paul's Hospital, Providence Health Care, Vancouver, British Columbia, Canada.
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Pharmacy, Providence Health Care, Vancouver, British Columbia, Canada.
- BugSeq Bioinformatics Inc., Vancouver, British Columbia, Canada.
ORCID-Profile: Aleksandra Stefanovic, Nancy Matic, Christopher F Lowe
Zitieren
APA
Stefanovic, A., Gowland, L., Ritchie, G., Lee, C., Chorlton, S., Matic, N., Leung, V., Payne, M., Lowe, C. F., & Romney, M. G. (2025). Mecillinam activity against multidrug-resistant Shigella sonnei and Shigella flexneri. Microbiology Spectrum, 13(3). https://doi.org/10.1128/spectrum.01006-24
Vancouver
Stefanovic A, Gowland L, Ritchie G, Lee C, Chorlton S, Matic N, et al. Mecillinam activity against multidrug-resistant Shigella sonnei and Shigella flexneri. Microbiology Spectrum. 2025;13(3). doi:10.1128/spectrum.01006-24
BibTeX
@article{Stefanovic2025,
author = {Stefanovic, Aleksandra and Gowland, Leah and Ritchie, Gordon and Lee, Colin and Chorlton, Sam and Matic, Nancy and Leung, Victor and Payne, Michael and Lowe, Christopher F and Romney, Marc G},
title = {Mecillinam activity against multidrug-resistant Shigella sonnei and Shigella flexneri},
journal = {Microbiology Spectrum},
year = {2025},
volume = {13},
number = {3},
doi = {10.1128/spectrum.01006-24}
}
EUVIMED